Crispr Therapeutics AG (CRSP) Stock Forecast & Price Target

Compare

9,333 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CRSP Analyst Ratings

Moderate Buy

14 Buy

6 Hold

0 Sell

Based on 20 analysts giving stock ratings to

Crispr

Therapeutics AG

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CRSP Stock 12 Month Forecast

Average Price Target

$68.65

▲(80.47%Upside)

Based on 20 Wall Street analysts offering 12 month price targets for Crispr Therapeutics AG in the last 3 months. The average price target is $68.65 with a high forecast of $105.00 and a low forecast of $35.00. The average price target represents a 80.47% change from the last price of $38.04.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"32":"$32","69":"$69","106":"$106","50.5":"$50.5","87.5":"$87.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":105,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$105.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":68.65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$68.65</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$35.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[32,50.5,69,87.5,106],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.95,42.184615384615384,47.41923076923077,52.65384615384616,57.88846153846154,63.12307692307692,68.3576923076923,73.5923076923077,78.82692307692308,84.06153846153846,89.29615384615386,94.53076923076924,99.76538461538462,{"y":105,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.95,39.38846153846154,41.82692307692308,44.26538461538462,46.70384615384616,49.142307692307696,51.580769230769235,54.019230769230774,56.45769230769231,58.89615384615385,61.33461538461539,63.77307692307693,66.21153846153847,{"y":68.65,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.95,36.800000000000004,36.650000000000006,36.5,36.35,36.2,36.050000000000004,35.9,35.75,35.6,35.45,35.3,35.15,{"y":35,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":53.81,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.74,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.95,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.85,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.58,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.76,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.15,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.36,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.59,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.92,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.14,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.73,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.95,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$105.00

Average Price Target$68.65

Lowest Price Target$35.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$38

Hold

-0.11%

Downside

Reiterated

06/04/25

The overall stock score for Crispr Therapeutics AG is primarily impacted by its financial performance and valuation challenges. Despite a strong balance sheet, the company faces operational inefficiencies and cash flow issues, leading to a lower financial performance score. Technical analysis provides mixed signals, reflecting neutral to slightly bearish momentum. Valuation concerns further weigh down the score, driven by negative earnings and the lack of a dividend yield. While recent corporate events are promising, they do not influence the score directly due to weight redistribution.

Sami CorwinWilliam Blair

William Blair

―

Buy

―

Reiterated

06/03/25

Promising Growth and Diversification Drive Buy Rating for Crispr Therapeutics AG

Unknown AnalystBernstein

Not Ranked

Bernstein

―

Hold

―

Assigned

05/27/25

Bernstein Sticks to Their Hold Rating for Crispr Therapeutics AG (CRSP)We rate the following companies Market-Perform: ALLO, ARWR, BIIB, CRSP, IONS, VRTX.

Silvan TuerkcanCitizens JMP

Citizens JMP

$86

Buy

126.08%

Upside

Reiterated

05/21/25

Citizens JMP reiterates Market Outperform Rating on CRISPR Therapeutics (CRSP)Citizens JMP analyst Silvan Tuerkcan reiterated a Market Outperform rating and $86.00 price target on CRISPR Therapeutics (NASDAQ: CRSP).

Mani ForooharLeerink Partners

Leerink Partners

$58→$56

Buy

47.21%

Upside

Reiterated

05/21/25

Leerink Partners Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)

Joon LeeTruist Financial

Truist Financial

―

Buy

―

Reiterated

05/20/25

Truist Financial Remains a Buy on Crispr Therapeutics AG (CRSP)

Gil BlumNeedham

Needham

$81

Buy

112.93%

Upside

Reiterated

05/20/25

Strategic Growth and De-risking: Gil Blum's Buy Rating on Crispr Therapeutics AG

Salim SyedMizuho Securities

Mizuho Securities

$99→$85

Buy

123.45%

Upside

Reiterated

05/20/25

Mizuho Securities Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)

Edward TenthoffPiper Sandler

Piper Sandler

$105

Buy

176.03%

Upside

Reiterated

05/20/25

Piper Sandler Keeps Their Buy Rating on Crispr Therapeutics AG (CRSP)

Kostas BiliourisBMO Capital

BMO Capital

$75

Buy

97.16%

Upside

Reiterated

05/20/25

Promising Potential of Crispr Therapeutics AG: Buy Rating Backed by Strategic Partnership and Diversified Pipeline

Mitchell KapoorH.C. Wainwright

H.C. Wainwright

$65

Buy

70.87%

Upside

Reiterated

05/20/25

Crispr Therapeutics AG: Strategic Advancements and Growth Potential Drive Buy Rating

Salveen RichterGoldman Sachs

Goldman Sachs

$57→$47

Hold

23.55%

Upside

Reiterated

05/19/25

Crispr Therapeutics AG: Promising Partnership with Sirius Therapeutics Amidst Clinical and Market Uncertainties Warrants Hold Rating

Yigal NochomovitzCiti

Citi

$82

Buy

115.56%

Upside

Reiterated

05/19/25

Strategic Expansion and Promising Ventures Drive Buy Rating for Crispr Therapeutics AG

Alec StranahanBank of America Securities

Bank of America Securities

$79

Buy

107.68%

Upside

Reiterated

05/19/25

Bank of America Securities Sticks to Its Buy Rating for Crispr Therapeutics AG (CRSP)

Gena WangBarclays

Barclays

$56→$42

Hold

10.41%

Upside

Reiterated

05/09/25

Crispr Therapeutics AG (CRSP) Gets a Hold from Barclays

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$38

Hold

-0.11%

Downside

Reiterated

06/04/25

Sami CorwinWilliam Blair

William Blair

―

Buy

―

Reiterated

06/03/25

Promising Growth and Diversification Drive Buy Rating for Crispr Therapeutics AG

Unknown AnalystBernstein

Not Ranked

Bernstein

―

Hold

―

Assigned

05/27/25

Bernstein Sticks to Their Hold Rating for Crispr Therapeutics AG (CRSP)We rate the following companies Market-Perform: ALLO, ARWR, BIIB, CRSP, IONS, VRTX.

Silvan TuerkcanCitizens JMP

Citizens JMP

$86

Buy

126.08%

Upside

Reiterated

05/21/25

Mani ForooharLeerink Partners

Leerink Partners

$58→$56

Buy

47.21%

Upside

Reiterated

05/21/25

Leerink Partners Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)

Joon LeeTruist Financial

Truist Financial

―

Buy

―

Reiterated

05/20/25

Truist Financial Remains a Buy on Crispr Therapeutics AG (CRSP)

Gil BlumNeedham

Needham

$81

Buy

112.93%

Upside

Reiterated

05/20/25

Strategic Growth and De-risking: Gil Blum's Buy Rating on Crispr Therapeutics AG

Salim SyedMizuho Securities

Mizuho Securities

$99→$85

Buy

123.45%

Upside

Reiterated

05/20/25

Mizuho Securities Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)

Edward TenthoffPiper Sandler

Piper Sandler

$105

Buy

176.03%

Upside

Reiterated

05/20/25

Piper Sandler Keeps Their Buy Rating on Crispr Therapeutics AG (CRSP)

Kostas BiliourisBMO Capital

BMO Capital

$75

Buy

97.16%

Upside

Reiterated

05/20/25

Promising Potential of Crispr Therapeutics AG: Buy Rating Backed by Strategic Partnership and Diversified Pipeline

Mitchell KapoorH.C. Wainwright

H.C. Wainwright

$65

Buy

70.87%

Upside

Reiterated

05/20/25

Crispr Therapeutics AG: Strategic Advancements and Growth Potential Drive Buy Rating

Salveen RichterGoldman Sachs

Goldman Sachs

$57→$47

Hold

23.55%

Upside

Reiterated

05/19/25

Crispr Therapeutics AG: Promising Partnership with Sirius Therapeutics Amidst Clinical and Market Uncertainties Warrants Hold Rating

Yigal NochomovitzCiti

Citi

$82

Buy

115.56%

Upside

Reiterated

05/19/25

Strategic Expansion and Promising Ventures Drive Buy Rating for Crispr Therapeutics AG

Alec StranahanBank of America Securities

Bank of America Securities

$79

Buy

107.68%

Upside

Reiterated

05/19/25

Bank of America Securities Sticks to Its Buy Rating for Crispr Therapeutics AG (CRSP)

Gena WangBarclays

Barclays

$56→$42

Hold

10.41%

Upside

Reiterated

05/09/25

Crispr Therapeutics AG (CRSP) Gets a Hold from Barclays

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Crispr Therapeutics AG

1 Month

xxx

Success Rate

12/18 ratings generated profit

Average Return

+9.43%

reiterated a xxx

rating 7 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +9.43% per trade.

3 Months

xxx

Success Rate

11/19 ratings generated profit

Average Return

+2.94%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 57.89% of your transactions generating a profit, with an average return of +2.94% per trade.

1 Year

Geulah LivshitsChardan Capital

Success Rate

18/41 ratings generated profit

Average Return

+17.08%

reiterated a buy rating 29 days ago

Copying Geulah Livshits's trades and holding each position for 1 Year would result in 43.90% of your transactions generating a profit, with an average return of +17.08% per trade.

2 Years

xxx

Success Rate

14/41 ratings generated profit

Average Return

+1.93%

reiterated a xxx

rating 29 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 34.15% of your transactions generating a profit, with an average return of +1.93% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CRSP Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CRSP has received 29 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. CRSP average Analyst price target in the past 3 months is 68.65.

Each month's total comprises the sum of three months' worth of ratings.

CRSP Financial Forecast

CRSP Earnings Forecast

Next quarter’s earnings estimate for CRSP is -$1.43 with a range of -$2.27 to -$0.93. The previous quarter’s EPS was -$1.58. CRSP beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year CRSP has Outperformed its overall industry.

CRSP Sales Forecast

Next quarter’s sales forecast for CRSP is $5.81M with a range of $0.00 to $31.07M. The previous quarter’s sales results were $865.00K. CRSP beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year CRSP has Outperformed its overall industry.

CRSP Stock Forecast FAQ

What is CRSP’s average 12-month price target, according to analysts?

Based on analyst ratings, Crispr Therapeutics’s 12-month average price target is 68.65.

What is CRSP’s upside potential, based on the analysts’ average price target?

Crispr Therapeutics has 80.47% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CRSP a Buy, Sell or Hold?

Crispr Therapeutics has a consensus rating of Moderate Buy which is based on 14 buy ratings, 6 hold ratings and 0 sell ratings.

What is Crispr Therapeutics’s price target?

The average price target for Crispr Therapeutics is 68.65. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $105.00 ,the lowest forecast is $35.00. The average price target represents 80.47% Increase from the current price of $38.04.

What do analysts say about Crispr Therapeutics?

Crispr Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 20 Wall Streets Analysts.

How can I buy shares of CRSP?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Crispr Therapeutics AG (CRSP) Stock Forecast & Price Target

CRSP Analyst Ratings

CRSP Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Crispr Therapeutics AG

CRSP Analyst Recommendation Trends

CRSP Financial Forecast

CRSP Earnings Forecast

CRSP Sales Forecast

CRSP Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts